 Long-term follow-up patients recurrent malignant gliomas adjuvant adoptive immunotherapy Between August October Denver Brain Tumor Research Group clinical trial autologous human recombinant lymphocytes patients recurrent high-grade gliomas trial involved surgical resection and/or decompression intracavitary implantation lymphokine-activated killer LAK cells autologous lymphocytes ASL plasma clot month lymphocytes Rickham reservoir catheter tumor bed LAK cells peripheral blood lymphocytes days ASL lectin- peripheral blood lymphocytes days patients group mean age years range years Karnofsky rating range mean Decadron dose entry mg/d range average number lymphocytes range date patients recurrent tumor growth median overall survival time weeks range median survival time immunotherapy weeks range significant difference survival immunotherapy patients previous chemotherapy use steroids prior chemotherapy vitro generation ASL LAK cells